Retension Pharmaceuticals, Inc. (RTSN)

Data as of Oct 13, 2026, from SEC Form 4 filings.

XNASNet insider buying (90d)Watch RTSN

See up to 3 months of RTSN. The 7-day demo opens the 1M and 3M ranges and puts RTSN on your watchlist.

Latest RTSN insider trades

Eric L. Keller - Officer
Open-market purchase$250K
Oct 13, 2026
Franklin M. Berger - Director
Open-market purchase$120K
Oct 13, 2026
Eric L. Keller - Officer

About Retension Pharmaceuticals, Inc. (RTSN)

Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure.

Listed: 2026
Exchange: XNAS
Sector: Health Care

https://www.retensionpharmaceuticals.com SEC filings for RTSN on EDGAR

RTSN Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Open-market purchase	2	30,800	$370K
Grant or award	5	277,718
Other acquisition / disposition	20	153,262

Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.

RTSN insider transactions (Form 4)

10 Form 4 filings on record, the earliest from Oct 9, 2026, newest first.

Date	Insider	Transaction	Security	Shares	Price	Value
Oct 13, 2026	Eric L. Keller - Officer	Open-market purchase	Common Stock	20,800	$12.00	$250K
Oct 13, 2026	Eric L. Keller - Officer	Other	Common Stock	9,662	-^{footnote F1}	-
Oct 13, 2026	Eric L. Keller - Officer	Other	Common Stock	31,368	-^{footnote F2}	-
Oct 13, 2026	Eric L. Keller - Officer	Grant or award	Stock Option (right to buy)	255,174	$0.00	-
Oct 13, 2026	Eric L. Keller - Officer	Other	Series A Convertible Preferred Stock	9,662	-^{footnote F1}	-
Oct 13, 2026	Eric L. Keller - Officer	Other	Series B Convertible Preferred Stock	31,368	-^{footnote F2}	-
Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR Footnote F2 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR
Oct 13, 2026	Paul Sweetnam - Officer	Other	Common Stock	4,026	-^{footnote F1}	-
Oct 13, 2026	Paul Sweetnam - Officer	Other	Common Stock	2,640	-^{footnote F2}	-
Oct 13, 2026	Paul Sweetnam - Officer	Other	Series A Convertible Preferred Stock	4,026	-^{footnote F1}	-
Oct 13, 2026	Paul Sweetnam - Officer	Other	Series B Convertible Preferred Stock	2,640	-^{footnote F2}	-
Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR Footnote F2 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR
Oct 13, 2026	Donald Olds - Director	Other	Common Stock	5,637	-^{footnote F1}	-
Oct 13, 2026	Donald Olds - Director	Other	Series A Convertible Preferred Stock	5,637	-^{footnote F1}	-
Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR
Oct 13, 2026	Pavan Cheruvu - Director	Grant or award	Stock Option (right to buy)	5,636	$0.00	-
Oct 13, 2026	Sabine Bisson - Officer	Other	Common Stock	1,611	-^{footnote F1}	-
Oct 13, 2026	Sabine Bisson - Officer	Other	Common Stock	2,504	-^{footnote F2}	-
Oct 13, 2026	Sabine Bisson - Officer	Other	Series A Convertible Preferred Stock	1,611	-^{footnote F1}	-
Oct 13, 2026	Sabine Bisson - Officer	Other	Series B Convertible Preferred Stock	2,504	-^{footnote F2}	-
Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR Footnote F2 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR
Oct 13, 2026	Franklin M. Berger - Director	Other	Common Stock	12,517	-^{footnote F1}	-
Oct 13, 2026	Franklin M. Berger - Director	Open-market purchase	Common Stock	10,000	$12.00	$120K
Oct 13, 2026	Franklin M. Berger - Director	Other	Series B Convertible Preferred Stock	12,517	-^{footnote F1}	-
Footnote F1 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR
Oct 13, 2026	Michael J. Berendt - Director	Other	Common Stock	4,026	-^{footnote F1}	-
Oct 13, 2026	Michael J. Berendt - Director	Other	Common Stock	2,640	-^{footnote F2}	-
Oct 13, 2026	Michael J. Berendt - Director	Other	Series A Convertible Preferred Stock	4,026	-^{footnote F1}	-
Oct 13, 2026	Michael J. Berendt - Director	Other	Series B Convertible Preferred Stock	2,640	-^{footnote F2}	-
Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR Footnote F2 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR
Oct 8, 2026	Michael J. Berendt - Director	Grant or award	Stock Option (right to buy)	5,636	$0.00	-
Oct 8, 2026	Donald Olds - Director	Grant or award	Stock Option (right to buy)	5,636	$0.00	-
Oct 8, 2026	Franklin M. Berger - Director	Grant or award	Stock Option (right to buy)	5,636	$0.00	-

Recent RTSN Form 8-K filings

Read RTSN company news

Oct 13, 2026Item 5.03, 9.01

Read the filing on SEC EDGAR

RTSN insider trading FAQ

What is the latest insider trade for RTSN?

Retension Pharmaceuticals, Inc. (RTSN) had 10 insider filings in the last 90 days, with the most recent on 2026-10-13. The full record for RTSN runs to 10 Form 4 filings, the earliest from 2026-10-09. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying RTSN stock?

2 insider purchases of RTSN were filed in the last 90 days, totaling $370K.

How many insiders are selling RTSN stock?

No insider sales of RTSN were filed in the last 90 days.

Where can I see RTSN SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects RTSN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Oct 13, 2026 - Eric L. Keller view on EDGAR
Oct 13, 2026 - Paul Sweetnam view on EDGAR
Oct 13, 2026 - Donald Olds view on EDGAR
Oct 13, 2026 - Pavan Cheruvu view on EDGAR
Oct 13, 2026 - Sabine Bisson view on EDGAR
Oct 13, 2026 - Franklin M. Berger view on EDGAR
Oct 13, 2026 - Michael J. Berendt view on EDGAR
Oct 9, 2026 - Michael J. Berendt view on EDGAR
Oct 9, 2026 - Donald Olds view on EDGAR

Related companies with recent insider activity

Learn more

How to read insider buying signals: What an open-market purchase by an insider can and cannot tell you.
Insider activity in Health Care: Where RTSN's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow RTSN with a 7-day demo

RTSN on your watchlist
Every RTSN Form 4 filing on record
Up to 3 months of RTSN price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Open-market purchase

30,800

$370K

Grant or award

277,718

Other acquisition / disposition

153,262

Date

Insider

Transaction

Security

Price

Value

Oct 13, 2026

Eric L. Keller - Officer

Open-market purchase

Common Stock

20,800

$12.00

$250K

Oct 13, 2026

Eric L. Keller - Officer

Other

Common Stock

9,662

-^{footnote F1}

Oct 13, 2026

Eric L. Keller - Officer

Other

Common Stock

31,368

-^{footnote F2}

Oct 13, 2026

Eric L. Keller - Officer

Grant or award

Stock Option (right to buy)

255,174

$0.00

Oct 13, 2026

Eric L. Keller - Officer

Other

Series A Convertible Preferred Stock

9,662

-^{footnote F1}

Oct 13, 2026

Eric L. Keller - Officer

Other

Series B Convertible Preferred Stock

31,368

-^{footnote F2}

Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR
Footnote F2 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR

Oct 13, 2026

Paul Sweetnam - Officer

Other

Common Stock

4,026

-^{footnote F1}

Oct 13, 2026

Paul Sweetnam - Officer

Other

Common Stock

2,640

-^{footnote F2}

Oct 13, 2026

Paul Sweetnam - Officer

Other

Series A Convertible Preferred Stock

4,026

-^{footnote F1}

Oct 13, 2026

Paul Sweetnam - Officer

Other

Series B Convertible Preferred Stock

2,640

-^{footnote F2}

Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR
Footnote F2 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR

Oct 13, 2026

Donald Olds - Director

Other

Common Stock

5,637

-^{footnote F1}

Oct 13, 2026

Donald Olds - Director

Other

Series A Convertible Preferred Stock

5,637

-^{footnote F1}

Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR

Oct 13, 2026

Pavan Cheruvu - Director

Grant or award

Stock Option (right to buy)

5,636

$0.00

Oct 13, 2026

Sabine Bisson - Officer

Other

Common Stock

1,611

-^{footnote F1}

Oct 13, 2026

Sabine Bisson - Officer

Other

Common Stock

2,504

-^{footnote F2}

Oct 13, 2026

Sabine Bisson - Officer

Other

Series A Convertible Preferred Stock

1,611

-^{footnote F1}

Oct 13, 2026

Sabine Bisson - Officer

Other

Series B Convertible Preferred Stock

2,504

-^{footnote F2}

Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR
Footnote F2 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR

Oct 13, 2026

Franklin M. Berger - Director

Other

Common Stock

12,517

-^{footnote F1}

Oct 13, 2026

Franklin M. Berger - Director

Open-market purchase

Common Stock

10,000

$12.00

$120K

Oct 13, 2026

Franklin M. Berger - Director

Other

Series B Convertible Preferred Stock

12,517

-^{footnote F1}

Footnote F1 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR

Oct 13, 2026

Michael J. Berendt - Director

Other

Common Stock

4,026

-^{footnote F1}

Oct 13, 2026

Michael J. Berendt - Director

Other

Common Stock

2,640

-^{footnote F2}

Oct 13, 2026

Michael J. Berendt - Director

Other

Series A Convertible Preferred Stock

4,026

-^{footnote F1}

Oct 13, 2026

Michael J. Berendt - Director

Other

Series B Convertible Preferred Stock

2,640

-^{footnote F2}

Footnote F1 (price): Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock had… Full note on SEC EDGAR
Footnote F2 (price): Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") converted automatically into one share of Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had… Full note on SEC EDGAR

Oct 8, 2026

Michael J. Berendt - Director

Grant or award

Stock Option (right to buy)

5,636

$0.00

Oct 8, 2026

Donald Olds - Director

Grant or award

Stock Option (right to buy)

5,636

$0.00

Oct 8, 2026

Franklin M. Berger - Director

Grant or award

Stock Option (right to buy)

5,636

$0.00